Levonorgestrel/Ethinylestradiol Cristers (Ethinylestradiol, Levonorgestrel)

The product contains levonorgestrel, a synthetic progestogen, and ethinylestradiol, a synthetic estrogen. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the luteinizing hormone surge that triggers ovulation, while also thickening cervical mucus and making the endometrium less suitable for implantation.

The specific dosing regimen for Levonorgestrel/Ethinylestradiol Cristers is determined by the prescribing clinician based on the product’s labeling and the patient’s medical profile. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Levonorgestrel/Ethinylestradiol is intended to prevent pregnancy and should not be used by women who are already pregnant. Its safety during breastfeeding is not fully established; clinicians typically advise caution and may recommend alternative contraception for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levonorgestrel/Ethinylestradiol combines a second‑generation progestogen with a low‑dose estrogen, offering a balance of efficacy and tolerability. Compared with newer formulations that may use different progestogens or lower estrogen doses, it has a well‑characterized safety profile but may carry a slightly higher risk of estrogen‑related side effects.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and discard any tablets that appear discolored or damaged.

Levonorgestrel/Ethinylestradiol Cristers are taken orally, usually once daily at the same time each day. The typical regimen involves a 21‑day active tablet phase followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. These events are rare but can be life‑threatening, especially in women with pre‑existing cardiovascular risk factors or who smoke heavily.

Women with a history of venous or arterial thromboembolism, uncontrolled hypertension, certain liver diseases, known or suspected breast cancer, or who are smokers over 35 years old should avoid this contraceptive. A thorough medical assessment is required before initiation.